文献速递血栓与止血

微小RNA作为(癌症相关)静脉血栓栓塞的预后生物标志物

MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2022-12-22

本文综述微小RNA(miRNA)在静脉血栓栓塞(VTE)病理生理中的作用及其作为VTE和癌症相关血栓(CAT)预测生物标志物的潜力。文章指出当前CAT风险预测模型表现欠佳,亟需新型生物标志物识别可从血栓预防中获益最大的患者。作者建议后续研究应具备足够样本量以确定最佳预测VTE和CAT的miRNA组合,并需在可比人群中开展验证研究。

要点

  • miRNA在VTE病理生理中具调控作用,且作为VTE生物标志物的证据日益增多。
  • 癌症患者VTE风险高于一般人群,但现有CAT风险预测模型表现欠佳。
  • 作者建议后续研究应足够样本量以确定最佳预测VTE和CAT的miRNA组合。

核心结论

  • miRNA作为独立或整合入现有风险模型的VTE和CAT生物标志物是否有价值,尚需在可比人群中开展验证研究后方可明确。
  • 作者提出后续研究应具备足够样本量以确定最佳预测VTE和CAT的miRNA组合。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • miRNA相对稳定、易于检测且可从血浆或其他体液中获取,是诊断和预测癌症及心血管疾病的有前景的生物标志物。
  • VTE是全球第三常见的心血管疾病,发病率和死亡率高。
  • 癌症患者较一般人群VTE风险增高。
  • CAT中鉴定的若干miRNA在VTE中也存在差异调控,为CAT病理生理提供线索。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 当前CAT风险预测模型表现欠佳。
  • 作者提出后续研究应具备足够样本量以确定最佳预测VTE和CAT的miRNA组合。
  • 需在可比人群中开展验证研究以明确miRNA作为VTE和CAT生物标志物的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MicroRNAs (miRNAs) are small noncoding RNAs with gene regulatory functions and are commonly dysregulated in disease states. As miRNAs are relatively stable, easily measured, and accessible from plasma or other body fluids, they are promising biomarkers for the diagnosis and prediction of cancer and cardiovascular diseases. Venous thromboembolism (VTE) is the third most common cardiovascular disease worldwide with high morbidity and mortality. The suggested roles of miRNAs in regulating the pathophysiology of VTE and as VTE biomarkers are nowadays more evidenced. Patients with cancer are at increased risk of developing VTE compared to the general population. However, current risk prediction models for cancer-associated thrombosis (CAT) perform suboptimally, and novel biomarkers are therefore urgently needed to identify which patients may benefit the most from thromboprophylaxis. This review will first discuss how miRNAs mechanistically contribute to the pathophysiology of VTE. Next, the potential use of miRNAs as predictive biomarkers for VTE in subjects without cancer is reviewed, followed by an in-depth focus on CAT. Several of the identified miRNAs in CAT were found to be differentially regulated in VTE as well, giving clues on the pathophysiology of CAT. We propose that subsequent studies should be adequately sized to determine which panel of miRNAs best predicts VTE and CAT. Thereafter, validation studies using comparable patient populations are required to ultimately unveil whether miRNAs-as standalone or incorporated into existing risk models-are promising valuable VTE and CAT biomarkers.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Anijs RJS, Nguyen YN, Cannegieter SC, et al. MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism. J Thromb Haemost. 2022. PMID: 36695398. doi:10.1016/j.jtha.2022.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。